We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

South-East Asia is facing an explosion in increasingly virulent and geographically mobile dengue fever.

Reported cases have increased from 300,000 a year in the 1980s to 925,000 since 2000 — and poor surveillance makes the WHO estimate that cases actually top 50 million annually. Vaccines are urgently needed.

But increasing human mobility means that all four strains of the virus often circulate simultaneously, and although infection gives immunity to individual strains, it can seriously exacerbate subsequent infections with different strains. So vaccines must target all four strains simultaneously.

Getting immune response levels right for tetravalent vaccines is tricky, partly because it is difficult to grow dengue virus in laboratories, and also because there is no convenient animal model for the disease.

But researchers are closing in on a solution, and three potential vaccines are now in phase II trials.

Scientists are persevering with conventional live attenuated vaccines, but also have chimeric candidates, including one that combines a yellow fever virus with several key dengue genes. 

Charity-funded preparations for large clinical trials, including epidemiological data collection and standardisation for diagnostic protocols, mean that promising vaccines should quickly move to phase III clinical trials — knocking years off the process.

Link to full article in Science